This fundamental study combines in vitro reconstitution experiments and molecular dynamics simulations to elucidate how membrane lipids are transported from the outer to the inner membrane of ...

Major construction has kicked off on Melbourne’s Suburban Rail Loop (SRL), with works full steam ahead to build a ...

Factory testing has been completed on DC Water’s first TBM to be used on the $819M design-build contract Potomac River Tunnel project being constructed by the CBNA-Halmar Clean Rivers JV, comprising ...

The transposition mix consisted of 25 µL of 2× TD buffer (20 mM Tris-HCl, 10 mM MgCl 2, 20% dimethylformamide), 2.5 µL of transposome assembly, 16.5 µL of PBS, 0.5 µL of 1% digitonin, 0.5 µL of 10% ...

He sought a second opinion at Fred Hutch Cancer Center, where a full body scan revealed that Crow had multiple myeloma. “I didn’t know what that was,” said Crow. “All I knew was that I had an ...

GPRC5D is a promising target for MM therapy, present in MM cells but minimally in normal immune cells, correlating with poorer patient outcomes. Strategies for targeting GPRC5D include bispecific ...

The indicated compound concentrations were added to a 40 nM annealed template in 1× Taq Buffer (10 mM Tris–HCl, pH 8.8, 50 mM KCl, Thermo Fisher Scientific), 1.5 mM MgCl 2, and 0.05 U/μL Taq ...

The positive results from ALLEVIATE-2 and ALLEVIATE-1 trials, and human abuse potential (HAP) studies comparing against various opioids, constitute the full Phase 3 program for cebranopadol in the ...

In 2018, Glock introduced its first crossover pistol, the G19X chambered for 9 mm Luger. This model came unconventionally mixed-matched with existing features found in other Glock pistols.

Having shown last week that its opioid alternative can reduce post-surgery pain, Tris Pharma is back with another slice of clinical data to show that the drug is less likely to be abused.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...

Tris Pharma has pointed to a phase 3 win for its pain relief drug as demonstrating the candidate’s potential to help resolve the opioid crisis. The company tested cebranopadol, a dual nociceptin ...